Long-Term Persistence of Spike Protein Antibody and Predictive Modeling of Antibody Dynamics After Infection With Severe Acute Respiratory Syndrome Coronavirus 2
Open Access
- 4 July 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 74 (7), 1220-1229
- https://doi.org/10.1093/cid/ciab607
Abstract
Antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been shown to neutralize the virus in vitro and prevent disease in animal challenge models on reexposure. However, the current understanding of SARS-CoV-2 humoral dynamics and longevity is conflicting. The COVID-19 Staff Testing of Antibody Responses Study (Co-Stars) prospectively enrolled 3679 healthcare workers to comprehensively characterize the kinetics of SARS-CoV-2 spike protein (S), receptor-binding domain, and nucleoprotein (N) antibodies in parallel. Participants screening seropositive had serial monthly serological testing for a maximum of 7 months with the Meso Scale Discovery Assay. Survival analysis determined the proportion of seroreversion, while 2 hierarchical gamma models predicted the upper and lower bounds of long-term antibody trajectory. A total of 1163 monthly samples were provided from 349 seropositive participants. At 200 days after symptoms, >95% of participants had detectable S antibodies, compared with 75% with detectable N antibodies. S antibody was predicted to remain detectable in 95% of participants until 465 days (95% confidence interval, 370–575 days) using a “continuous-decay” model and indefinitely using a “decay-to-plateau” model to account for antibody secretion by long-lived plasma cells. S-antibody titers were correlated strongly with surrogate neutralization in vitro (R2 = 0.72). N antibodies, however, decayed rapidly with a half-life of 60 days (95% confidence interval, 52–68 days). The Co-Stars data presented here provide evidence for long-term persistence of neutralizing S antibodies. This has important implications for the duration of functional immunity after SARS-CoV-2 infection. In contrast, the rapid decay of N antibodies must be considered in future seroprevalence studies and public health decision-making. This is the first study to establish a mathematical framework capable of predicting long-term humoral dynamics after SARS-CoV-2 infection. NCT04380896.Funding Information
- Wellcome Trust (201470/Z/16/Z, 220565/Z/20/Z)
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health (1R01AI146338)
- CHARITY (VC0921)
This publication has 53 references indexed in Scilit:
- The Maintenance of Memory Plasma CellsFrontiers in Immunology, 2019
- B Cell Responses: Cell Interaction Dynamics and DecisionsCell, 2019
- Individual and Population Trajectories of Influenza Antibody Titers Over Multiple Seasons in a Tropical CountryAmerican Journal of Epidemiology, 2017
- Living on Three Time Scales: The Dynamics of Plasma Cell and Antibody Populations Illustrated for Hepatitis A VirusPLoS Computational Biology, 2012
- Mechanisms that determine plasma cell lifespan and the duration of humoral immunityImmunological Reviews, 2010
- HIV-1 Envelope Induces Memory B Cell Responses That Correlate with Plasma Antibody Levels after Envelope gp120 Protein Vaccination or HIV-1 InfectionThe Journal of Immunology, 2009
- Antibodies and B Cell Memory in Viral ImmunityImmunity, 2007
- Disappearance of Antibodies to SARS-Associated Coronavirus after RecoveryThe New England Journal of Medicine, 2007
- Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccineVaccine, 2007
- Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significanceRespirology, 2006